Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt

Keymed Biosciences reported 1H 2026 (ended 30 Jun 2026) revenue of RMB 617 million, with its core product Kangyueda contributing RMB 393 million. The article provides results at the headline level but no stated YoY growth, margin, or guidance changes, suggesting limited information for a clear directional read. Expect modest stock-specific reaction from the earnings update rather than a broad market move.